CryptoHypeBuster
OpenAI Buys Orchestra Bio to Put AI Agents in Charge of Drug Development Grunt Work
Decrypt · Tue, 20 Oct 2026 21:46:04 GMT
Hype 30/100 · Market impact 0/100 · Breaking 45/100
OpenAI has acquired Orchestra Bio and is integrating its drug-program agents into Rosalind, OpenAI’s life sciences suite, to try to shorten the decade-plus process of bringing a medicine to patients.